| Identification | Back Directory | [Name]
10H-5,7-Ethenopyrazolo[4,3-g]pyrido[3,2-m]pyrrolo[1,2-k][1,4,6,9,11]oxatetraazacyclotetradecin-11(12H)-one, 2,18-difluoro-1,2,3,13,14,19b-hexahydro-14-methyl-, (2S,14S,19bR)- | [CAS]
2403703-30-8 | [Synonyms]
zurletrectinib
10H-5,7-Ethenopyrazolo[4,3-g]pyrido[3,2-m]pyrrolo[1,2-k][1,4,6,9,11]oxatetraazacyclotetradecin-11(12H)-one, 2,18-difluoro-1,2,3,13,14,19b-hexahydro-14-methyl-, (2S,14S,19bR)- | [Molecular Formula]
C19H19F2N7O2 | [MOL File]
2403703-30-8.mol | [Molecular Weight]
415.4 |
| Hazard Information | Back Directory | [Uses]
Zurletrectinib is a potent tyrosine kinase inhibitor. Zurletrectinib serves as an antineoplastic agent. Zurletrectinib can used for research of preventing TRK-mediated related diseases, such as tumors[1][2]. | [References]
[1] Kong NX, et al. Preparation of the heterocyclic compounds as trk inhibitor: World Intellectual Property Organization, WO2020001415. 2020-01-02.
[2] WHO Drug Information-World Health Organization (WHO). |
|
|